Visit
iwMDS 2022
24–26 June 2022 | Miami, FL, USA
VJHemOnc is pleased to be the official media partner for the 1st International Workshop on Myelodysplastic Syndromes (iwMDS), which was held in Miami, FL, on 24-26 June 2022.
The workshop brought together leading international clinicians and researchers in an in-person forum to discuss the current status and recent advances in MDS with the aim to optimize clinical care.
Morphologic classification of MDS, defining the boundary between MDS and other myeloid neoplasms
Morphologic Classification of MDS focus on dysplasia and blasts
John Bennett University of Rochester Medical Center, Rochester, NY, United States
Morphologic correlates of cytogenetic and molecular alterations in MPNs
Sanam Loghavi MD Anderson Cancer Center, Houston, TX, United States
Defining the boundary between MDS and other MPNs
Robert Hasserjian Massachusetts General Hospital, Boston, MA, United States
Non-neoplastic morphologic mimics of myelodysplastic syndromes
Mina Xu New Haven, CT, United States
Q&A discussion: MDS Morphology
John Bennett, Sanam Loghavi, Robert Hasserjian, Mina Xu
How can we improve efficiency of drug approval? – Part I
The FDA’s perspective on new therapy development for MDS
Kelly Norsworthy Johns Hopkins Medicine, Baltimore, MD, United States
European & global regulatory harmonization efforts
Guillermo Sanz La Fe University Hospital, Valencia, Spain
Meaningful clinical benefit and totality of data
Mikkael Sekeres Sylvester Comprehensive Cancer Center, Miami, FL, United States
Academic perspective: What should approval endpoints be?
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
How can we improve efficiency of drug approval? – Part II
An overview of MDS MyeloMATCH efforts
Olatoyosi Odenike Duchossois Center for Advanced Medicine, Chicago, IL, United States
Biomarker-driven clinical trials & early endpoints in NCI - MyeloMATCH
Richard Little National Cancer Institute, Rockville, MD, United States
BCL2 modulation in MDS
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia
Role of oral HMAs in MDS
Guillermo Garcia-Manero University of Texas MD Anderson Cancer Center, Houston, TX, United States
How can we improve efficiency of drug approval? – Part III
Imetelstat and HIF inhibitors evolving use in MDS
Valeria Santini University of Florence, Florence, Italy
Is there still a way forward for APR-246 in TP53-mutated MDS?
Andrew Brunner Massachusetts General Hospital, Boston, MA, United States
Updates on SY-1425
Hetty Carraway Cleveland Clinic, Cleveland, OH, United States
XPO1 therapeutic manipulation in MDS
Justin Taylor Sylvester Comprehensive Cancer Center, Miami, FL, United States
Roundtable Discussion: How can we improve efficiency of drug approval?
Hetty Carraway, Olatoyosi Odenike, Andrew Brunner, Justin Taylor
Inflammation, immune dysregulation and targeting in MDS – Part I
The role of TIM-3 in pathogenesis of MDS
Vijay Kuchroo Brigham and Women's Hospital, Boston, MA, United States
CD47 pathway and its therapeutic targeting
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Targeting LAIR and PD-1H (VISTA) in MDS/AML
Tae Kon Kim Vanderbilt University, Nashville, TN, United States
Inflammation, immune dysregulation and targeting in MDS – Part II
PD1/PDL-1/CTLA-4, and TIM-3 targeting in MDS
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
IRAK inhibitors in MDS and AML
Uwe Platzbecker University Hospital in Leipzig, Leipzig, Germany
CAR T-cell therapy in MDS and AML
Gail Roboz Weill Medical College of Cornell University, New York City, NY, United States
NK therapeutic modulation for MDS and AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Targeting the NLRP3 inflammasome in MDS
Alan List Precision BioSciences, Durham, NC, United States
Roundtable Discussion: Inflammation, immune dysregulation and targeting in MDS
Uwe Platzbecker, Alan List, David Sallman, Daniel Starczynowski
Updates in classification and risk stratification
MDS classification updates
Robert Hasserjian Massachusetts General Hospital, Boston, MA, United States
The IPSS-Molecular
Rafael Bejar University of California, San Diego, CA, United States
The EuroMDS Molecular Prognostic Tool
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
The MDS Clinical Research Consortium Molecular Prognostic Tool
Aziz Nazha Thomas Jefferson University, Philadelphia, PA, United States
Genetic predisposition to MDS
Jane Churpek University of Wisconsin Carbone Cancer Center, Madison, WI, United States
Roundtable Discussion: Updates in classification and risk stratification in MDS
Rafael Bejar, Aziz Nazha, Robert Hasserjian, Jane Churpek
Clonal hematopoiesis and Pre-MDS states
Understanding approach to risk of hematologic malignancies in CH
Zhuoer Xie Rochester, MN, United States
Linking CH to progression of disease
Mrinal Patnaik Rochester, MN, United States
Could we prevent therapy-related myeloid malignancies?
Eric Padron Moffitt Cancer Center, Tampa, FL, United States
Roundtable discussion: Clonal hematopoiesis and pre-MDS states
Eric Padron, Mrinal Patnaik, Zhuoer Xie
Splicing factors and RNA pathobiology/epigenetics
An update on MDS animal models
Stephanie Halene Yale School of Medicine, New Haven, CT, United States
Non-interventional and big data research in MDS
Artificial intelligence in MDS
Aziz Nazha Thomas Jefferson University, Philadelphia, PA, United States
NHLBI natural history registry for MDS
Amy DeZern Johns Hopkins University School of Medicine, Baltimore, MD, United States
Patient-reported outcomes and quality-of-life instruments in MDS
Fabio Efficace Feinberg School of Medicine, Chicago, IL, United States
Incorporating patient-related factor risk stratification in clinical trials
Rena Buckstein Sunnybrook Health Sciences Centre
Key highlights from iwMDS 2022
Roundtable discussion: Key highlights from iwMDS 2022
Amer Zeidan, Rena Buckstein, Valeria Santini
iwMDS 2022 has been supported by:
